Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report)’s stock price was up 2.2% during mid-day trading on Friday . The stock traded as high as $1.72 and last traded at $1.64. Approximately 442,337 shares were traded during mid-day trading, an increase of 21% from the average daily volume of 365,530 shares. The stock had previously closed at $1.61.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Iterum Therapeutics in a research note on Friday, June 21st.
View Our Latest Stock Report on ITRM
Iterum Therapeutics Trading Up 2.2 %
Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. Research analysts anticipate that Iterum Therapeutics plc will post -1.76 earnings per share for the current year.
About Iterum Therapeutics
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Recommended Stories
- Five stocks we like better than Iterum Therapeutics
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Top 3 Beverage Stocks: Summer Earnings Reveal Key Trends
- Are Penny Stocks a Good Fit for Your Portfolio?
- This Financial Stock’s Earnings Signal a Buying Opportunity
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Social Platform Stock Hits New Highs: Is More Growth Ahead?
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.